The Application of Zishen Yutai Pill in Aged Women Undergoing IVF-ET
Key facts
- Who runs it
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- Where
- China12 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 1,467 people enrolled
- Started
- 4 Mar 2019
- Ended
- 14 Sept 2024
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Zishen Yutai Pill
- Placebo
- Record updated
- 25 March 2025
Who can take part
- Age
- 35 years to 42 years
- Sex
- Women only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- infertile women aged ≥35 and ≤42 years
- intend to undergo IVF/ICSI-ET (GnRH-a long protocol or GnRH-ant protocol)
- BMI<28kg/m2
- bilateral ovaries exist
- patients who voluntarily signed the informed consent and agreed to be followed up as required by the study protocol
Who cannot take part
- repeated implantation failure (previous three times or more IVF/ICSI-ET failure)
- endometrial diseases that have not been cured
- known diseases that are not suitable for undergoing assisted reproductive technology or at the present not suitable for pregnancy
- adenomyosis, uterine line constricted by uterine fibroid
- untreated bilateral hydrosalpinx
- patients who have taken traditional Chinese medicine or Chinese patent medicine for infertility treatment in the last month(30 days); Exit Criteria:
- subjects who have adverse events cannot be tolerated
- severe breach of the protocol
- for subjects who exit due to personal or unpredictable reasons, please describe specific details
- subjects considered inappropriate to continue to participate in the study for other medical reasons
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
To explore the application of Zishen Yutai Pill in controlled ovarian stimulation and effect on pregnancy outcome in aged women undergoing in vitro fertilization-embryo transfer.
The 2 groups in the trial
- Zishen Yutai pill groupTreatment being tested
Patients who undergo the long-term protocol will start taking Zishen Yutai Pill on the day of pituitary suppression, 5g three times a day (Stopping on the first 1-4 days of menstruation), and patients who undergo the antagonist protocol will start taking Zishen Yutai Pill on the 19th to 23rd day of the previous menstruation cycle, 5g three times a day (Stopping on the first 1-4 days of menstruation). The drug will be taken till 2 weeks after transplantation. If the test result is confirmed as biochemical pregnancy (HCG\>50 IU/L), patients continue to take pills till 3 weeks after the clinical pregnancy determined by the ultrasound. If it is determined that the pregnancy test is negative, stop the drug.
Treatment: Zishen Yutai Pill
- Placebo groupPlacebo, for comparison
Patients who undergo the long-term protocol will start taking Placebo on the day of pituitary suppression, 5g three times a day (Stopping on the first 1-4 days of menstruation), and patients who undergo the antagonist protocol will start taking Placebo on the 19th to 23rd day of the previous menstruation cycle, 5g three times a day (Stopping on the first 1-4 days of menstruation). The drug will be taken till 2 weeks after transplantation. If the test result is confirmed as biochemical pregnancy (HCG\>50 IU/L), patients continue to take pills till 3 weeks after the clinical pregnancy determined by the ultrasound. If it is determined that the pregnancy test is negative, stop the drug.
Treatment: Placebo
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- The Application of Zishen Yutai Pill in Aged Women Undergoing in Vitro Fertilization-embryo Transfer: a Multi-center Double-blind Randomized Controlled Trial
- Record updated
- 25 March 2025